Binge Eating Disorder - Pipeline Review, H2 2015

Published: Dec, 2015 | Pages: 45 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Binge Eating Disorder - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Binge Eating Disorder - Pipeline Review, H2 2015', provides an overview of the Binge Eating Disorder's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Binge Eating Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Binge Eating Disorder and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Binge Eating Disorder
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Binge Eating Disorder and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Binge Eating Disorder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Binge Eating Disorder pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons To Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Binge Eating Disorder
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Binge Eating Disorder pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Binge Eating Disorder Overview 6
Therapeutics Development 7
Pipeline Products for Binge Eating Disorder - Overview 7
Binge Eating Disorder - Therapeutics under Development by Companies 8
Binge Eating Disorder - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Early Stage Products 11
Unknown Stage Products 12
Binge Eating Disorder - Products under Development by Companies 13
Binge Eating Disorder - Companies Involved in Therapeutics Development 14
Eli Lilly and Company 14
Heptares Therapeutics Limited 15
Lightlake Therapeutics Inc. 16
Omeros Corporation 17
Polleo Pharma Limited 18
Sunovion Pharmaceuticals Inc. 19
Teva Pharmaceutical Industries Limited 20
Binge Eating Disorder - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 29
armodafinil - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
dasotraline - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
LY-2940094 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
naloxone hydrochloride - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
OMS-527 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Small Molecules for Binge Eating Disorder - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Binge Eating Disorder - Recent Pipeline Updates 39
Binge Eating Disorder - Dormant Projects 42
Binge Eating Disorder - Discontinued Products 43
Appendix 44
Methodology 44
Coverage 44
Secondary Research 44
Primary Research 44
Expert Panel Validation 44
Contact Us 44
Disclaimer 45

List of Tables

Number of Products under Development for Binge Eating Disorder, H2 2015 7
Number of Products under Development by Companies, H2 2015 8
Comparative Analysis by Late Stage Development, H2 2015 9
Comparative Analysis by Clinical Stage Development, H2 2015 10
Comparative Analysis by Early Stage Development, H2 2015 11
Comparative Analysis by Unknown Stage Development, H2 2015 12
Products under Development by Companies, H2 2015 13
Binge Eating Disorder - Pipeline by Eli Lilly and Company, H2 2015 14
Binge Eating Disorder - Pipeline by Heptares Therapeutics Limited, H2 2015 15
Binge Eating Disorder - Pipeline by Lightlake Therapeutics Inc., H2 2015 16
Binge Eating Disorder - Pipeline by Omeros Corporation, H2 2015 17
Binge Eating Disorder - Pipeline by Polleo Pharma Limited, H2 2015 18
Binge Eating Disorder - Pipeline by Sunovion Pharmaceuticals Inc., H2 2015 19
Binge Eating Disorder - Pipeline by Teva Pharmaceutical Industries Limited, H2 2015 20
Assessment by Monotherapy Products, H2 2015 21
Number of Products by Stage and Target, H2 2015 23
Number of Products by Stage and Mechanism of Action, H2 2015 25
Number of Products by Stage and Route of Administration, H2 2015 27
Number of Products by Stage and Molecule Type, H2 2015 28
Binge Eating Disorder Therapeutics - Recent Pipeline Updates, H2 2015 39
Binge Eating Disorder - Dormant Projects, H2 2015 42
Binge Eating Disorder - Discontinued Products, H2 2015 43